Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as ... - BioSpace
Genmab announced Phase 1/2 study data of Rina-S, an FRα-targeted ADC, showing a 50% ORR in ovarian cancer patients treated with Rina-S 120 mg/m² Q3W, regardless of FRα expression levels. The study results were presented at ESMO 2024, with Rina-S 120 mg/m² selected for further evaluation in a Phase 3 trial expected to start in 2024.
Related Clinical Trials
Reference News
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as ... - BioSpace
Genmab announced Phase 1/2 study data of Rina-S, an FRα-targeted ADC, showing a 50% ORR in ovarian cancer patients treated with Rina-S 120 mg/m² Q3W, regardless of FRα expression levels. The study results were presented at ESMO 2024, with Rina-S 120 mg/m² selected for further evaluation in a Phase 3 trial expected to start in 2024.